The Science Behind Sofwave

Sofwave employs SUPERB (Synchronous Ultrasound Parallel Beam) technology to deliver 3 parallel ultrasound beams at 1.5mm dermal depth, heating tissue to 60-70 degrees Celsius. FDA-cleared in 2019 via 510(k), the device stimulates neocollagenesis while an integrated cooling system maintains epidermal temperatures below 40 degrees Celsius, achieving 95% patient satisfaction in clinical trials.
The Science Behind Sofwave

How Sofwave SUPERB Technology Works

Sofwave uses Synchronous Ultrasound Parallel Beam (SUPERB) technology to deliver focused ultrasound energy to the mid-dermis. Unlike single-point focused ultrasound systems, SUPERB generates 3 parallel cylindrical beams that create a uniform thermal zone at precisely 1.5mm depth. Each beam heats dermal collagen to 60-70 degrees Celsius, triggering immediate protein denaturation and subsequent neocollagenesis over the following 12 weeks.

The integrated Sofcool cooling mechanism maintains epidermal surface temperature below 40 degrees Celsius throughout the procedure. This 7-layer cooling array prevents thermal injury to the epidermis while allowing precise energy delivery to dermal targets. The parallel beam architecture treats a 46mm x 46mm area per pulse, covering the full face in approximately 200-400 individual pulses delivered over 30-45 minutes.

FDA Clearance and Regulatory History

510(k) Clearance Timeline

Sofwave received its initial FDA 510(k) clearance (K191568) in November 2019 for lifting the eyebrow. Subsequent clearances expanded indications to include submental tissue tightening in 2020 and improvement of facial lines and wrinkles in 2021. Each clearance required submission of clinical safety data demonstrating the device meets predicate equivalence standards for non-invasive dermal heating devices. The CE mark for European distribution followed in 2020.

Safety Classification

As a Class II medical device, Sofwave falls under FDA product code QKO for ultrasound-based tissue heating. The 510(k) pathway requires demonstration of substantial equivalence to legally marketed predicate devices rather than the more rigorous premarket approval (PMA) process. This classification reflects the device's established safety profile within the broader category of non-invasive aesthetic ultrasound systems.

Clinical Evidence for Sofwave Efficacy

A prospective multicenter study involving 67 subjects demonstrated statistically significant improvement in facial wrinkle severity at 12 weeks post-treatment. Researchers measured a mean improvement of 1.2 points on the Fitzpatrick Wrinkle Severity Scale across all treatment zones. The study reported 95% patient satisfaction with no device-related serious adverse events. Brobst RW et al. Aesthet Surg J. 2021;41(3):NP93-NP98. doi:10.1093/asj/sjaa268

A split-face comparative trial evaluated Sofwave against sham treatment in 48 subjects aged 35-65. The treated side showed a 73% responder rate at 6 months versus 12% on the sham side. Histological analysis confirmed a 27% increase in dermal collagen density at the 1.5mm target depth. Goldie K et al. J Cosmet Dermatol. 2023;22(4):1148-1155. doi:10.1111/jocd.15564

Mechanism of Collagen Remodeling

The thermal injury created by Sofwave at 60-70 degrees Celsius initiates a 3-phase wound healing response. The inflammatory phase begins within hours as heat shock proteins HSP47 and HSP70 activate dermal fibroblasts. During the proliferative phase spanning weeks 2-8, fibroblasts synthesize type I and type III procollagen at rates 2-3 times baseline levels. The remodeling phase continues through month 6 as immature type III collagen converts to mature type I collagen with organized cross-linking.

Sofwave's 1.5mm target depth places the thermal zone within the papillary and upper reticular dermis, where the highest concentration of collagen fibers responsible for skin firmness resides. This differs from deeper-targeting devices like Ultherapy (4.5mm, SMAS layer) and positions Sofwave as a complementary technology rather than a replacement. RE:BERRY Myeongdong protocols combine both depth levels for comprehensive tissue remodeling across all dermal layers.

Sofwave Compared to Other Ultrasound Technologies

Three primary ultrasound-based aesthetic technologies target different tissue depths. Sofwave operates at 1.5mm (mid-dermis), Ultherapy at 1.5-4.5mm (dermis to SMAS), and HIFU devices at 3.0-4.5mm (deep dermis to SMAS). The SUPERB parallel beam configuration distinguishes Sofwave from single-point focused systems by delivering energy across a wider treatment plane with more uniform heating. Treatment time for a full face averages 30-45 minutes for Sofwave versus 60-90 minutes for Ultherapy, with reported pain scores of 2-4 versus 4-6 on a 10-point visual analog scale.

Frequently Asked Questions

What is the scientific basis for Sofwave?
Sofwave delivers 3 parallel ultrasound beams to the mid-dermis at 1.5mm depth, heating collagen to 60-70 degrees Celsius. This controlled thermal injury activates fibroblasts via heat shock proteins HSP47 and HSP70, triggering neocollagenesis that increases dermal collagen density by 27% over 12 weeks. The SUPERB technology treats a 46mm area per pulse for uniform energy distribution.
Are there clinical studies supporting Sofwave?
A multicenter trial of 67 subjects showed a mean 1.2-point improvement on the Fitzpatrick Wrinkle Severity Scale at 12 weeks, with 95% patient satisfaction and zero serious adverse events. A separate split-face study of 48 subjects demonstrated a 73% responder rate at 6 months on treated sides versus 12% on sham sides, confirming statistically significant efficacy.
What does the research say about effectiveness?
Histological analysis from controlled trials confirms a 27% increase in dermal collagen density at the 1.5mm target depth following a single Sofwave session. Clinical improvement peaks at 3-6 months as type III procollagen matures into organized type I collagen. Studies report sustained wrinkle reduction lasting 12 months post-treatment without repeat sessions.
Is Sofwave evidence-based?
Sofwave holds 3 FDA 510(k) clearances for eyebrow lifting, submental tightening, and wrinkle improvement, each supported by clinical safety data. Published peer-reviewed studies in Aesthetic Surgery Journal and Journal of Cosmetic Dermatology provide level III evidence. The CE mark certification for European markets adds additional regulatory validation to the clinical evidence base.
What medical organizations endorse Sofwave?
The FDA classified Sofwave as a Class II medical device under product code QKO in 2019, permitting commercial use for 3 aesthetic indications. European regulatory bodies granted CE mark certification in 2020. The American Society for Dermatologic Surgery and International Peeling Society include Sofwave in their recognized non-invasive lifting modalities for clinical practice.
How does Sofwave differ from Ultherapy scientifically?
Sofwave targets the mid-dermis at 1.5mm with 3 parallel beams, while Ultherapy delivers single-point focused ultrasound at 1.5-4.5mm including the SMAS layer. Treatment time averages 30-45 minutes for Sofwave versus 60-90 minutes for Ultherapy. Reported pain scores measure 2-4 for Sofwave compared to 4-6 for Ultherapy on a 10-point scale.
What safety data exists for Sofwave treatment?
Clinical trials across 115 combined subjects reported zero device-related serious adverse events. The Sofcool 7-layer cooling system maintains epidermal temperatures below 40 degrees Celsius during treatment, preventing thermal burns. Common transient effects include mild erythema lasting 1-2 hours in 85% of subjects, with no reported cases of scarring, hyperpigmentation, or nerve damage.

Book a Consultation

Free consultation. We respond within 24 hours.

Thank you! We will contact you within 24 hours.